Stellarex EnduraCoat technology

Patented Stellarex EnduraCoat is a differentiated technology designed for performance in complex and severely calcified lesions and patients with multiple comorbidities.

Hybrid paclitaxel + polyethylene glycol = top-tier outcomes

Hybrid paclitaxel (PTX) formulation + PEG excipient

Amorphous PTX

enhances coating durability and prompt drug availability for immediate action and short-term residency7

Crystalline PTX

forms drug depots that dissolve into tissue slowly for sustained residency7

Polythene glycol (PEG) excipient

PEG’s durability, adhesion, flexibility, elongation and elasticity may help prevent premature drug loss during handling, tracking and inflation

PEG HAp

Designed for performance in calcium

  • PEG forms strong ionic bonds with hydroxyl apatite (HAp),12 the primary component of calcified atherosclerotic lesions, which may limit PTX washout in the presence of calcium
  • PEG may protect PTX, giving it time to be absorbed into vessel when calcium is present

High transfer efficiency and effective residency9,11

Stellarex EnduraCoat technology achieves uniform and acute drug transfer and sustained tissue residency at therapeutic levels through 28 days, minimizing restenosis.

ng PTX/mg of tissue
0.1
1
10
100
Days after treatment
0
5
10
15
20
25
30
35
Stellarex
In.Pact
Lutonix

Low particulate loss

Stellarex demonstrates low particulate loss,9 which may reduce the risk of downstream embolization and, at the same time, enable a low therapeutic drug dose.

Number of particulate ≥10µm/mL (x100)
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
10000
1,946
Stellarex

9,183
In.Pact

3,297
Lutonix

Anti-restenotic effect

A comparative study of Stellarex versus PTA in a swine model of in-stent restenosis demonstrates Stellarex DCB’s efficacy at 28 days, indicated by minimal luminal loss and consistent treatment effect.9

Treatment (Day 1)
Day 28
Stellarex
PTA
Day 1
Day 28

See more about the Stellarex difference

Download info sheet